Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Pierre Bedossa.

Newcastle AuthorsTitleYearFull text
Professor Pierre Bedossa
Professor Quentin Anstee
A Randomized Controlled Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis2024
Kristy Wonders
Dr Dina Tiniakos
Professor Pierre Bedossa
Professor Quentin Anstee
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study2023
Professor Quentin Anstee
Professor Pierre Bedossa
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study2023
Professor Quentin Anstee
Professor Pierre Bedossa
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis2023
Kristy Wonders
Dr Dina Tiniakos
Professor Pierre Bedossa
Professor Cliff Brass
Professor Quentin Anstee
et al.
Machine learning algorithm improves detection of NASH (NAS-based) and at-risk NASH: a development and validation study2023
Dr Katherine Johnson
Dr Peter Leary
Dr Olivier Govaere
Dr Matthew Barter
Sarah Charlton
et al.
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance2022
Professor Alastair Burt
Professor Pierre Bedossa
Dr Dina Tiniakos
Fifty years of impact on liver pathology: a history of the Gnomes2021
Dr Olivier Govaere
Dr Dina Tiniakos
Professor Pierre Bedossa
Dr Simon Cockell
Dr Massimo Younes
et al.
NASH limits anti-tumor surveillance in immunotherapy-treated HCC2021
Professor Pierre Bedossa
Professor Quentin Anstee
Professor Arun Sanyal
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study2020
Professor Pierre Bedossa
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease2020
Professor Quentin Anstee
Professor Pierre Bedossa
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study2020
Professor Quentin Anstee
Dr Rebecca Darlay
Dr Simon Cockell
Dr Olivier Govaere
Dr Dina Tiniakos
et al.
Genome-Wide Association Study of Non-Alcoholic Fatty Liver and Steatohepatitis in a Histologically-Characterised Cohort2020
Dr Timothy Hardy
Kristy Wonders
Dr Massimo Younes
Professor Pierre Bedossa
Entesar Betelmal
et al.
The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease2020
Dr Olivier Govaere
Dr Simon Cockell
Dr Dina Tiniakos
Dr Rachel Queen
Dr Massimo Younes
et al.
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis2020
Professor Quentin Anstee
Professor Pierre Bedossa
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease2019
Professor Quentin Anstee
Professor Pierre Bedossa
Professor Arun Sanyal
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial2019
Dr Marie Boyle
Dr Dina Tiniakos
Dr Olivier Govaere
Dr Massimo Younes
Professor Stuart McPherson
et al.
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease2019
Professor Arun Sanyal
Professor Quentin Anstee
Professor Pierre Bedossa
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis2019
Professor Alastair Burt
Professor Pierre Bedossa
Professor Helen Reeves
Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)2018
Professor Chris Day
Professor Pierre Bedossa
Substantial variability of the diagnostic accuracy of serum fibrosis markers across multiple cohorts of nash patients in various centers : the case for the negative predictive value2015
Professor Pierre Bedossa
Professor Alastair Burt
Dr Dina Tiniakos
Dr John Brain
Dr Yvonne Bury
et al.
Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease2014
Professor Pierre Bedossa
Professor Alastair Burt
Dr Dina Tiniakos
Well differentiated hepatocellular neoplasm of uncertain malignant potential: Proposal for a new diagnostic category2014